Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-3201b and Irinotecan in Recurrent Small Cell Lung Cancer
NCT03879798Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valemetostat in small cell lung cancer (SCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2019; status: terminated.
02
Drugs
valemetostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03879798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879798.